Pulmatrix launches iSPERSE, a novel inhaled dry powder drug delivery platform
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.
Asthmapolis, the FDA-cleared mobile health solution for asthma and COPD, today announces it received a second investment from the California HealthCare Foundation.